By activating STAT1/IRF1 signaling through IFN-γ in tumor-associated macrophages, SP140 promotes PD-L1 expression, which has been reported as both a therapeutic target and a predictive biomarker of immunotherapy response in cancers such as metastatic melanoma and head and neck neoplasms [39]. This evidence concerns the gene IRF1 and head and neck neoplasm.